A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

Tan, E-H; Ramlau, R; Pluzanska, A; Kuo, H-P; Reck, M; Milanowski, J; S-K Au, J; Felip, E; Yang, P-C; Damyanov, D; Orlov, S; Akimov, M; Delmar, P; Essioux, L; Hillenbach, C; Klughammer, B; McLoughlin, P; Baselga, J

doi:10.1093/annonc/mdp520

Public

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

Shared by NobleBlocks on Feb 1, 2010 • 12:00 AM UTC

Authors:

E-H Tan

R Ramlau

A Pluzanska

Abstract

BACKGROUND: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clini...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!